SYNTHESIS AND SCREENING OF PI3K INHIBITOR PRODRUGS FOR TREATMENT OF PROSTATE CANCER

Prostate cancer is the most common non-skin cancer in American men. At the current time, there is no effective treatment for men with metastatic prostate cancer. Androgen ablation is the most successful systemic treatment for prostate cancer. However, the cancer eventually recurs as androgen-independent prostate cancer. Phosphoinositide 3-kinases (PI3Ks) are involved in several imperative cellular functions such as growth and survival; therefore, inhibition of PI3K induces apoptosis (programmed cell death) and suppresses tumor growth. Several compounds have been identified as PI3K inhibitors, e.g., wortmannin, LY294002, and, ZSTK474, but all have low selectivity. We have addressed the specificity of current PI3K inhibitors by developing PSA (prostate-specific antigen)-activated analogues of known PI3K inhibitors LY294002 and ZSTK474.

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2012

Author dc:creator

• Pinder, Tanya

• LY294002

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/37309

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/37309